Downloads
-
AAV Analytics: Key Considerations When Developing A Clinical Program
4/25/2024
Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.
-
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
4/25/2024
BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months.
-
Integrating Quality Processes And Documentation After A Merger
4/25/2024
If your company is undergoing a merger, you must juggle operations while ensuring minimal disruptions. You'll need a holistic view of QMS and SOPs to harmonize procedures.
-
Bulk Filling Of Drug Substance | Accurate Aliquoting
4/24/2024
Bulk filling drug substances in traditional facilities is often a lengthy, manual process where operators are relied upon to adjust pump controls to achieve accurate filling. This method, spanning multiple shifts, increases process risk through errors that can compromise accuracy.
-
Clone, Strain, And Viral Construct Screening Executed For You
4/24/2024
Evaluate your clones, strains, and viral constructs in our bioreactors with flexible scale out.
Benefits
Select the best clone by evaluating larger experimental cohorts
Make the most informed, data-driven selection by leveraging our fleet of 250mL and 5L Culture bioreactors to screen your clones, strains and viral constructs.
Defer your capital equipment spend
Evaluate your clones, strains and viral constructs without the need for new capital equipment.
Transparent, real-time data provided by a team of experts
Painless technology transfer with live data relayed via our cloud-connected systems. We have >95% success rate with >22,000 runs successfully executed.
-
Leverage Bioreactor Capacity When You Need It With Culture Bioreactors
4/24/2024
Gain access to Culture bioreactors when you need rapid overflow experimental capacity.
Benefits
Progress studies faster
Run overflow projects and conduct parallel experiments with Culture to reduce time and alleviate bottlenecks.
Stay agile in your capacity planning
Scale your workload at Culture according to your current needs. Respond rapidly to surging demands.
Eliminate your capital equipment spend
Leverage Culture’s facility quickly to avoid building out lab space, spending capital on equipment, and hiring specialized staff.
-
Streamlining Single-Use Assemblies In The Bulk-Fill Step Of Downstream Processing
4/24/2024
Single-use (SU) systems and components are growing in demand as they offer minimal contamination risk. Review a standardized SU assembly for bulk-fill processing that aims to improve efficiency.
-
NK Cell Therapies: How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach
4/24/2024
We caught up with Chris Horan, Artiva Biotherapeutics' CTO, to discuss natural killer cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.
-
Evaluating CAR T-Cell Therapy Vascular Recruitment, Trafficking, And Killing
4/24/2024
Learn about a more human-relevant platform that enables researchers to assess the trafficking and killing efficiency of immunotherapy as well as the proof-of-concept of immuno-oncology co-therapy.
-
Large-Scale API Production Services
4/23/2024
Ensuring commercial success at every juncture, we employ a consultative and phase-appropriate methodology that's tailored to your specific needs.